GlaxoSmithKline
Also known as: Barrier Therapeutics/ Stiefel, a GSK Company | Bellus Health Inc. - a GSK company | CTI-1, LLC | Darier | GlasoSmithKline | GLAXO GRP ENGLAND | GLAXO GRP LTD | GlaxoSmithKline | GLAXOSMITHKLINE | GlaxoSmithKline AG, Switzerland | GlaxoSmithKline Biologicals | Glaxosmithkline Biologicals S.A. | GLAXOSMITHKLINE CON | GLAXOSMITHKLINE CONS | GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare) | GlaxoSmithKline Intellectual Property Development Ltd. England | GlaxoSmithKline LLC | GlaxoSmithKline, LLC | GLAXOSMITHKLINE LLC | Glaxosmithkline/Quintiles | GlaxoSmithKlline | GSK-CIHR Research Chair in Respiratory Health Care Delivery, | GSK Vaccines Institute for Global Health (GVGH) | GSK Vaccines Institute For Global Health S.r.l. | Stiefel, a GSK Company | Tech Observer
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1990First marketed drug
Jun 1, 1982First NDA
Dec 30, 1985Last known activity
May 31, 2026
Timeline
1980s
- Jun 1, 1982
GlaxoSmithKline— Founded
- Dec 19, 1986
clavulanate— Marketing Organization
2000s
- Jan 1, 2000
Glaxo Wellcome— Acquired
- Jan 1, 2000
SmithKline Beecham— Acquired
- Aug 20, 2004
estradiol— NDA Secondary Org
- Jan 1, 2005
Corixa— Acquired
- Sep 1, 2005
ID Biomedical Corporation, Quebec— Acquired
- Jan 1, 2006
CNS Inc— Acquired
- Jan 1, 2007
Praecis Pharmaceuticals— Acquired
- Jan 1, 2007
RelGen— Acquired
- Apr 27, 2007
fluticasone— NDA Organization
- Jan 1, 2008
Genelabs Technologies— Acquired
- Sep 30, 2008
Reliant Pharmaceuticals— Acquired
- Jan 1, 2009
Sirtris Pharmaceuticals— Acquired
- Jan 1, 2009
Stiefel Laboratories— Acquired
2010s
- Jan 1, 2010
Laboratorios Phoenix— Acquired
- Jan 1, 2010
NovaMin Technology— Acquired
- Jan 1, 2012
Cellzome— Acquired
- Jan 1, 2012
Human Genome Sciences— Acquired
- Jan 1, 2013
Okairos— Acquired
- Jan 1, 2015
GlycoVaxyn— Acquired
- Jan 22, 2019
Tesaro— Acquired
2020s
- Apr 14, 2022
Sierra Oncology, Inc.— Acquired - May 31, 2022
Affinivax— Acquired
- Apr 18, 2023
Bellus Health Inc— Acquired
- Jan 10, 2025
IDRx, Inc.— Acquired
Drugs by trial phase (1275 distinct, 5016 trials)
Phase 4 (161 own, 135 via acquisition)
Phase 3 (168 own, 84 via acquisition)
Phase 2 (320 own, 73 via acquisition)
Phase 1 (270 own, 35 via acquisition)
Other trials (22 own, 7 via acquisition)
Indications
Approved for
- Alopecia
- Anemia, Aplastic
- Anxiety
- Anxiety Disorders
- Asthma
- Atrial Fibrillation
- Breast Neoplasms
- Bronchitis, Chronic
- Carcinoma, Renal Cell
- Cluster Headache
- Cystitis, Interstitial
- Depressive Disorder
- Dermatitis, Atopic
- Diabetes Mellitus, Type 2
- Digestive System Diseases
- Emphysema
- HIV Infections
- Impetigo
- Infections
- Intraabdominal Infections
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lice Infestations
- Major Depressive Disorder
- Malaria
- Malaria, Falciparum
- Malaria, Vivax
- Melanoma
- Migraine Disorders
- Motion Sickness
- Muscle Contraction
- Nausea
- Peptic Ulcer
- Pneumonia, Pneumocystis
- Postoperative Nausea and Vomiting
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Purpura, Thrombocytopenic, Idiopathic
- Reproductive Tract Infections
- Respiratory Tract Infections
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sarcoma
- Scabies
- Schizophrenia
- Sepsis
- Skin Diseases
- Skin Diseases, Eczematous
- Skin Diseases, Infectious
- Spasm
- Staphylococcal Skin Infections
- Stomach Ulcer
- Tachycardia, Ventricular
- Thrombocytopenia
- Tobacco Use Disorder
- Vertigo
- Vomiting
Studied for
- Acidosis
- Acidosis, Lactic
- Acne Vulgaris
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Acute Lung Injury
- Adenocarcinoma
- Adenocarcinoma, Follicular
- Adenocarcinoma of Lung
- Adenomyosis
- Agammaglobulinemia
- Agnosia
- Alcoholism
- Alopecia
- Alopecia Areata
- Alzheimer Disease
- Amyloid Neuropathies
- Amyloid Neuropathies, Familial
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Iron-Deficiency
- Anemia, Sickle Cell
- Aneurysm
- Angina Pectoris
- Angina, Stable
- Angina, Unstable
- Ankle Injuries
- Anthrax
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Anxiety Disorders
- Aortic Aneurysm
- Aortic Aneurysm, Thoracic
- Apnea
- Arrhythmias, Cardiac
- Arteritis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Asthma, Exercise-Induced
- Astrocytoma
- Atherosclerosis
- Atrial Fibrillation
- Atrophy
- Attention Deficit Disorder with Hyperactivity
- Autoimmune Diseases
- Bacterial Infections
- Bell Palsy
- Biliary Tract Neoplasms
- Binge-Eating Disorder
- Bipolar Disorder
- Blister
- Blood Platelet Disorders
- Borderline Personality Disorder
- Brain Diseases
- Brain Neoplasms
- Breast Diseases
- Breast Neoplasms
- Breast Neoplasms, Male
- Bronchial Spasm
- Bronchiectasis
- Bronchiolitis
- Bronchiolitis Obliterans
- Bronchitis
- Bronchitis, Chronic
- Bulimia
- Burns
- Cachexia
- Cancer Pain
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Ductal
- Carcinoma, Ductal, Breast
- Carcinoma, Hepatocellular
- Carcinoma, Islet Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cardiomyopathies
- Cardiomyopathy, Dilated
- Cardiovascular Diseases
- Celiac Disease
- Cellulitis
- Cervical Intraepithelial Neoplasia
- Chickenpox
- Cholangiocarcinoma
- Cholangitis
- Cholestasis
- Cholestasis, Intrahepatic
- Chondrosarcoma
- Chronic Disease
- Churg-Strauss Syndrome
- Clostridium Infections
- Cluster Headache
- Cognition Disorders
Marketed drugs (159)
Subsidiaries (22 direct, 51 total across the full acquisition tree)
- Affinivax
- Bellus Health Inc
- Cellzome
- CNS Inc
- Corixa
- Genelabs Technologies
- Glaxo Wellcome
- GlycoVaxyn
- Human Genome Sciences
- ID Biomedical Corporation, Quebec
- IDRx, Inc.
- Laboratorios Phoenix
- NovaMin Technology
- Okairos
- Praecis Pharmaceuticals
- RelGen
- Reliant Pharmaceuticals
- Sierra Oncology, Inc.
- Sirtris Pharmaceuticals
- SmithKline Beecham
- Stiefel Laboratories
- Tesaro
- Barrier Therapeutics L2
- Beecham L2
- Burroughs Wellcome L2
- Connetics L2
- Coulter Pharmaceutical L2
- GenQuest, Inc L2
- Glaxo L2
- Innodia L2
- Ribi Immunochem L2
- SmithKline Beckman L2
- Affymax L3
- Allen & Hanburys L3
- Allergan (1948) L3
- C.L. Bencard L3
- International Clinical Laboratories L3
- PediaMed Pharmaceuticals L3
- S.E. Massengill Company L3
- Smith, Kline & French L3
- Soltec Research L3
- Allergan L4
- Smith and Shoemaker L4
- Cobalt Labs Inc L5
- Esprit Pharma L5
- John K. Smith and Company L5
- MAP Pharmaceuticals L5
- Oculex Pharmaceuticals L5
- Oculinium L5
- Skinmedica L5
- Vicept Therapeutics L5
Recent trials (50)
- NCT05582083Lead sponsorN/A—
- NCT05582083Study directorN/A—
- NCT03702036Lead sponsorN/A—
- NCT03702036Study directorN/A—
- NCT03763370Lead sponsorN/A—
- NCT05448170Lead sponsorN/A—
- NCT05448170Study directorN/A—
- NCT07285239CollaboratorPhase 3May 31, 2026
- NCT07286331Lead sponsorPhase 3Mar 5, 2026
- NCT07286266Lead sponsorPhase 3Mar 3, 2026
- NCT07104799CollaboratorPhase 1Jan 31, 2026
- NCT07268053CollaboratorEarly Phase 1Jan 31, 2026
- NCT07227311Lead sponsorPhase 2Jan 14, 2026
- NCT07263594CollaboratorPhase 1/Phase 2Dec 31, 2025
- NCT07050732CollaboratorPhase 2Dec 31, 2025
Details
- Founded
- Mexico City, MX Jun 1, 1982
- First NDA
- Dec 30, 1985
- Last known activity
- May 31, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval
Notes
--- Pre-folding founded info: 2000-01-01 London GB https://en.wikipedia.org/wiki/GlaxoSmithKline ---